LENZ data in CMML and AML

Multiple patients in the PREACH-M Phase 2/3 study being completed in Australia have elected to receive LENZ under compassionate use, once their 2 years cycle on the study has been completed and they are still well. All are high-risk patients and the vast majority remain well, in some cases 3 or 4 years into treatment, which is longer than would be expected on current standard of care only.